Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
about
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesDrugs derived from phage display: from candidate identification to clinical practiceClinical potential of necitumumab in non-small cell lung carcinomaCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsAntibody phage display libraries: contributions to oncology.Advances in phage display technology for drug discovery.Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic reviewTargeting the epidermal growth factor receptor in solid tumor malignancies.Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.Necitumumab for non-small cell lung cancer.Antibodies as stratagems against cancer.Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.Antibodies to watch in 2014.Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
P2860
Q26995399-D1BCB8FC-0BD4-4968-99D2-598AC7C524EFQ27007101-366AD1D4-7497-4DDD-BCA8-05B145DDA650Q28072850-84404391-9E89-4758-A783-0E77916DCEE6Q28086768-DA5E2EF8-D3AF-48C6-8C66-A35D44A673A9Q34323991-325618B6-8FEB-4CE4-A350-FF633218D645Q35614190-D5D0AB10-A5C4-4F5D-AFD4-1B10B3987EA4Q36337063-728B2125-AB05-4D02-876A-86709DF167F3Q37990044-98656077-2576-4C56-AFF3-D024B106146BQ38032893-9692EE7B-CDD1-4BBA-80DF-9971E1E1E242Q38200654-EC087D7E-EFDF-4632-AA5F-2E347F7E110AQ38221293-1E190618-AE3B-4850-B522-2CE627AC174CQ38519582-B59785C4-6CDE-4259-B7C7-138BC37D7D9DQ38688747-2CCDB35F-07A7-4E98-82F0-F2B319007F80Q41526288-948B93F7-1B7A-47CC-AE74-A63BA2570272Q42461882-6278CDF6-7A7A-48DC-AB29-3AAE491756EFQ51507476-EAEF80FE-25DF-4408-8C00-F79659F27CD0Q51698764-2DBAFAD5-0228-4633-8123-20BACBE9FB9BQ55054705-FE7EE667-40B2-4F1F-B7B5-1F8C94E5C36B
P2860
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Necitumumab in the treatment o ...... nical to clinical development.
@en
Necitumumab in the treatment o ...... nical to clinical development.
@nl
type
label
Necitumumab in the treatment o ...... nical to clinical development.
@en
Necitumumab in the treatment o ...... nical to clinical development.
@nl
prefLabel
Necitumumab in the treatment o ...... nical to clinical development.
@en
Necitumumab in the treatment o ...... nical to clinical development.
@nl
P2860
P1476
Necitumumab in the treatment o ...... nical to clinical development.
@en
P2093
Rodrigo Dienstmann
P2860
P304
P356
10.1517/14712598.2011.595709
P407
P577
2011-06-16T00:00:00Z